Back to News
Market Impact: 0.45
Kobayashi in $3.2 Billion Buyout Talks After Red-Yeast Scandal
Source: Bloomberg
M&A & RestructuringPrivate Markets & VentureHealthcare & BiotechLegal & Litigation
Kobayashi Pharmaceutical is reportedly considering a private-equity buyout offer exceeding ¥500 billion ($3.2 billion). The potential transaction comes after the Japanese health-products company was embroiled in a supplement-contamination scandal involving suspected deaths, potentially offering an exit route despite substantial reputational and legal risks.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Musk says Tesla will refund some Cybertruck deposits, defends decision to end production
- UniCredit CEO Plots Commerzbank Governance Overhaul
- Why is Nvidia’s Jensen Huang at the centre of a US-China spy scandal?
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion